Trials / Unknown
UnknownNCT06148233
CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Huashan Hospital · Academic / Other
- Sex
- All
- Age
- 60 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
To explore the diagnostic value of \[18F\]CSF-23 brain imaging for CSF1R expression in Alzheimer's disease. PET imaging with this PET tracer was used to assess the role and expression of CSF1R in AD and to evaluate the level and safety of abnormal present imaging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | [18F]CSF-23 | Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[18F\]CSF-23 in a single dose. |
Timeline
- Start date
- 2023-09-15
- Primary completion
- 2024-06-16
- Completion
- 2024-09-14
- First posted
- 2023-11-28
- Last updated
- 2023-11-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06148233. Inclusion in this directory is not an endorsement.